PriceTargets.com logo

Voyager Therapeutics - VYGR Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $17.00
  • Forecasted Upside: 201.42%
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 7 Buy Ratings
  • 1 Strong Buy Ratings
$5.64 As of 11/15/2024 01:00 AM ET
▼ -0.58 (-9.32%)

This chart shows the closing price for VYGR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Voyager Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VYGR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VYGR

Analyst Price Target is $17.00
▲ +201.42% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Voyager Therapeutics in the last 3 months. The average price target is $17.00, with a high forecast of $30.00 and a low forecast of $7.00. The average price target represents a 201.42% upside from the last price of $5.64.

This chart shows the closing price for VYGR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 9 polled investment analysts is to buy stock in Voyager Therapeutics. This rating has held steady since September 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/26/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/24/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/22/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/20/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
5/20/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
8/18/2024
  • 1 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/17/2024
  • 1 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/16/2024

Latest Recommendations

  • 1 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/14/2024Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
11/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
10/24/2024HC WainwrightReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
10/16/2024Leerink PartnrsUpgradeStrong-Buy
10/16/2024Leerink PartnersInitiated CoverageOutperform$15.00
8/20/2024HC WainwrightReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
8/7/2024WedbushLower TargetNeutral ➝ Neutral$8.00 ➝ $7.00
7/31/2024HC WainwrightReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
5/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$30.00
5/15/2024OppenheimerReiterated RatingOutperform ➝ Outperform$18.00
5/14/2024WedbushLower TargetNeutral ➝ Neutral$10.00 ➝ $8.00
3/26/2024GuggenheimInitiated CoverageBuy$22.00
3/19/2024HC WainwrightInitiated CoverageBuy$30.00
3/7/2024CitigroupInitiated CoverageBuy$16.00
1/2/2024Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$9.00 ➝ $14.00
9/18/2023Chardan CapitalReiterated RatingNeutral
8/7/2023OppenheimerReiterated RatingOutperform ➝ Outperform$16.00
5/10/2023Truist FinancialInitiated CoverageBuy$18.00
3/9/2023OppenheimerInitiated CoverageOutperform$14.00
3/9/2022Chardan CapitalBoost Target$4.00 ➝ $6.00
1/3/2022UBS GroupLower Target$14.00 ➝ $6.00
11/2/2021Chardan CapitalLower TargetNeutral$5.50 ➝ $4.00
10/7/2021Robert W. BairdUpgradeNeutral ➝ Outperform$6.00 ➝ $9.00
8/11/2021BenchmarkLower TargetBuy$20.00 ➝ $9.00
7/1/2021Chardan CapitalReiterated RatingNeutral
6/21/2021Compass PointInitiated CoverageBuy$45.00
5/13/2021Robert W. BairdReiterated RatingHold$6.00
4/19/2021Morgan StanleyLower TargetEqual Weight$7.00 ➝ $6.00
3/1/2021Robert W. BairdReiterated RatingOutperform ➝ Buy$18.00
2/26/2021Robert W. BairdDowngradeOutperform ➝ Neutral$18.00 ➝ $6.00
2/3/2021WedbushDowngradeOutperform ➝ Neutral$13.00 ➝ $6.00
2/3/2021Morgan StanleyLower TargetEqual Weight ➝ Hold$13.00 ➝ $7.00
2/3/2021Chardan CapitalLower TargetNeutral$15.00 ➝ $6.50
2/3/2021BTIG ResearchDowngradeBuy ➝ Neutral
1/25/2021HC WainwrightInitiated CoverageBuy$12.00
12/23/2020Cantor FitzgeraldDowngradeOverweight ➝ Neutral$15.00 ➝ $10.00
12/23/2020Raymond JamesDowngradeOutperform ➝ Market Perform
11/11/2020BTIG ResearchLower Target$31.00 ➝ $18.00
11/11/2020OppenheimerDowngradeOutperform ➝ Market Perform
11/10/2020WedbushLower TargetOutperform$19.00 ➝ $13.00
11/10/2020Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$10.00
11/10/2020Raymond JamesDowngradeStrong-Buy ➝ Outperform$28.00 ➝ $17.00
10/13/2020WedbushLower TargetHold ➝ Outperform$24.00 ➝ $19.00
8/14/2020Chardan CapitalReiterated RatingHold$15.00
8/12/2020WedbushReiterated RatingBuy$24.00
8/4/2020HC WainwrightLower TargetBuy$18.00 ➝ $14.00
5/13/2020NomuraReiterated RatingBuy$16.00
5/8/2020Chardan CapitalReiterated RatingHold$15.00
4/15/2020Morgan StanleyLower TargetEqual Weight$14.00 ➝ $13.00
3/30/2020Nomura SecuritiesLower TargetBuy$37.00 ➝ $16.00
3/19/2020BenchmarkInitiated CoverageBuy$18.00
3/6/2020Chardan CapitalReiterated RatingHold$20.00
3/4/2020HC WainwrightLower TargetBuy$26.00 ➝ $18.00
3/4/2020Morgan StanleyLower TargetEqual Weight$15.00 ➝ $14.00
3/4/2020WedbushLower TargetOutperform$34.00 ➝ $27.00
2/5/2020OppenheimerInitiated CoverageOutperform$26.00
11/24/2019Evercore ISIReiterated RatingHold$18.00
(Data available from 11/17/2019 forward)

News Sentiment Rating

0.32 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 29 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
4/21/2024
  • 4 very positive mentions
  • 26 positive mentions
  • 5 negative mentions
  • 2 very negative mentions
Mentions as of
5/21/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/20/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/20/2024
  • 9 very positive mentions
  • 15 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
8/19/2024
  • 4 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
9/18/2024
  • 10 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/18/2024
  • 9 very positive mentions
  • 28 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
Mentions as of
11/17/2024

Current Sentiment

  • 9 very positive mentions
  • 28 positive mentions
  • 5 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Voyager Therapeutics logo
Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
Read More

Today's Range

Now: $5.64
Low: $5.59
High: $6.15

50 Day Range

MA: $6.62
Low: $5.64
High: $8.07

52 Week Range

Now: $5.64
Low: $5.59
High: $11.72

Volume

795,871 shs

Average Volume

675,726 shs

Market Capitalization

$308.11 million

P/E Ratio

7.94

Dividend Yield

N/A

Beta

0.89

Frequently Asked Questions

What sell-side analysts currently cover shares of Voyager Therapeutics?

The following equities research analysts have issued stock ratings on Voyager Therapeutics in the last year: Canaccord Genuity Group Inc., Citigroup Inc., Guggenheim, HC Wainwright, Leerink Partners, Leerink Partnrs, Oppenheimer Holdings Inc., StockNews.com, Wedbush, and Wells Fargo & Company.
View the latest analyst ratings for VYGR.

What is the current price target for Voyager Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Voyager Therapeutics in the last year. Their average twelve-month price target is $17.00, suggesting a possible upside of 201.4%. HC Wainwright has the highest price target set, predicting VYGR will reach $30.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $7.00 for Voyager Therapeutics in the next year.
View the latest price targets for VYGR.

What is the current consensus analyst rating for Voyager Therapeutics?

Voyager Therapeutics currently has 1 hold rating, 7 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VYGR will outperform the market and that investors should add to their positions of Voyager Therapeutics.
View the latest ratings for VYGR.

What other companies compete with Voyager Therapeutics?

Other companies that are similar to Voyager Therapeutics include Adverum Biotechnologies, Jounce Therapeutics, CASI Pharmaceuticals, bluebird bio and Applied Genetic Technologies. Learn More about companies similar to Voyager Therapeutics.

How do I contact Voyager Therapeutics' investor relations team?

Voyager Therapeutics' physical mailing address is 75 SIDNEY STREET, CAMBRIDGE MA, 02139. The company's listed phone number is (857) 259-5340 and its investor relations email address is [email protected]. The official website for Voyager Therapeutics is www.voyagertherapeutics.com. Learn More about contacing Voyager Therapeutics investor relations.